SUNRISE Aims to Create a Comprehensive, Engaging, and Sustainable Digital Health Promotion Program That Not Only Addresses Immediate Health Behaviours But Also Instils Lifelong Healthy Habits Among Adolescents. It is a Unique, Digitally Enhanced Program Combining Different Digital Solutions With New

ConditionCancer
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age10-19
SponsorBiobizkaia Health Research Institute

About this trial

SUNRISE aims to create a comprehensive, engaging, and sustainable digital health promotion program that not only addresses immediate health behaviours but also instills lifelong healthy habits among adolescents. By integrating cutting-edge digital tools with traditional educational settings, SUNRISE seeks to bridge the gap between knowledge and practice, making cancer prevention a tangible and achievable goal for young people. This study represents a significant step towards reducing the future burden of cancer through early and innovative preventive measures.

The SUNRISE project aims to test its interventions on students across eight European countries, including Greece, Switzerland, Slovenia, Spain, Cyprus, Italy, Belgium, and Romania. This study focuses on integrating a unique, digitally enhanced program combining different digital solutions with new methods to change adolescent health behaviour through social media campaigns, social bot platforms, educational games, and health-related advertising content into the school environment, targeting students aged 10 to 19 years.

The program emphasizes inclusivity, ensuring participation from both urban and rural regions and socially disadvantaged groups such as ethnic minorities and migrants. By addressing diverse socio-economic, cultural, and environmental contexts, SUNRISE aspires to create a universally applicable and impactful intervention.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Minimum Age: Students must be at least 10 years old at the time of enrolment.

Devices and Internet Access: Students must have access to an electronic device with Internet connectivity.

Informed Consent: Students must provide their signed informed consent to participate in the study.

Parental Consent: Students, when necessary, must obtain and submit signed informed consent from a parent or legal guardian.

Disqualifiers

Age Restrictions: Students who are younger than 10 years or older than the established age range for participation.

Consent Issues: Students who have not signed the informed consent form or do not have signed informed consent from their parents or legal guardians.

Follow-up Limitations: Students who are unable to commit to the follow-up period of at least 18 months or are unlikely to complete the study.

Trial population

Secondary and upper secondary students between 10 and 19 years old (at time of recruitment), who are freely willing to participate in the study.

Trial design

Design model

Other

Time perspective

Prospective

Treatments tested in this trial

  • SUNRISE program

    Other intervention

    The program will use several solutions, each focusing on different aspects of health promotion: * SmartCoach, a mobile phone-based life-skills training program, focuses on self-management, social skills, and substance use resistance. * Social robots and conversational assistants aim to engage students through interactive sessions on health topics like diet and physical activity. * Educational and serious games enhance knowledge and resistance to unhealthy food marketing, providing an engaging way to learn about advertising tactics and healthy eating. * The influencer campaign tackles nutritional misinformation by using content created by influencers to educate adolescents on detecting and critically evaluating misleading health information. * Health and advertisement educational module aims to educate students on recognizing deceptive advertising and making informed choices about their health.

Treatment groups

4,000 Participants
are divided into 2 treatment groups
Group A: Control0 interventions
Group B: Intervention1 intervention

Trial outcomes

Primary outcomes

1

Feasibility of the Digitally-Enhanced Program

This will be measured by evaluating the usage and engagement with the intervention, through a in-house authoring and monitoring tool. This tool will include the questionnaires, statistical displays, interactive visualization of data and reporting tools for monitoring and assessment of the intervention outcomes.

Time frame
18 months

Secondary outcomes

1

Frequency of tobacco cigarette smoking

Determined by the number of days on which tobacco cigarettes were smoked in the last 30 days

Time frame
The secondary outcomes will also be assessed at baseline, 6 months, and 18 months follow-up
2

Prevalence and frequency of other nicotine products use

Determined by the number of days on which other nicotine products, e.g., vape, e-cigarette, e-shisha, snus or nicotine pouches, were consumed in the last 30 days

Time frame
The secondary outcomes will also be assessed at baseline, 6 months, and 18 months follow-up
3

Prevalence and frequency of cannabis use

Measured by the number of cannabis (containing THC) consumption days in the preceding 30 days

Time frame
The secondary outcomes will also be assessed at baseline, 6 months, and 18 months follow-up
4

Prevalence and frequency of alcohol use

Assessed by the number of alcohol use days in the preceding 30 days

Time frame
The secondary outcomes will also be assessed at baseline, 6 months, and 18 months follow-up

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Biobizkaia Health Research Institute

Lead sponsor

FEDERAZIONE ITALIANA DELLE ASSOCIAZIONI DI VOLONTARIATO IN ONCOLOGIA

Collaborator

Hellenic Mediterranean University

Collaborator

University Ghent

Collaborator

University of Zurich

Collaborator

FISABIO (Foundation for the Promotion of Healthcare and Biomedical Research in the Valencian Community)

Collaborator

The Oncology Institute "Prof. Dr. Ion Chiricuţă" Cluj-Napoca

Collaborator

Cyprus Association of Cancer Patients and Friends (PASYKAF)

Collaborator

Alma Mater Europaea University

Collaborator

This trial is not recruiting at the moment. You can still explore other options: